The UK government is calling in reinforcements to fix its pharmaceutical pricing problem. Whitehall officials are assembling a panel of senior pharma executives to help design a replacement for the country's current drug-pricing framework, which is showing its age.
Representatives from AstraZeneca Plc (AZN) and GSK Plc (GSK) will join the working group, according to Sky News. Their mission: figure out what should replace the Voluntary Scheme for Branded Medicines Pricing and Access, known as VPAG, which expires in roughly three years.
This isn't just a bureaucratic housekeeping exercise. The pharmaceutical industry has been increasingly vocal about the current system's shortcomings, arguing that VPAG's rebate requirements and pricing expectations are actively discouraging investment in the UK. Several companies have threatened to delay or scale back research and development commitments if the pricing structure doesn't change.
The stakes got higher in December when the UK struck a deal with the US to eliminate tariffs on British pharmaceutical exports to America. Sounds good, right? Well, there's a catch. In exchange for zero import taxes on UK-made drugs for three years, the National Health Service agreed to pay 25% more for new US medicines. That's a significant cost increase for a healthcare system already under budget pressure.
The working group will explore various alternatives to the current model. One option on the table is outcomes-based pricing, where drug costs would be tied to how well medicines actually perform. Another concept involves linking prices to the amount of research, development, and manufacturing activity a company conducts inside the UK—essentially rewarding pharmaceutical firms that invest locally.
The urgency isn't theoretical. Merck & Co. Inc. (MRK) recently announced it's canceling plans for a $1.36 billion (1 billion Sterling pounds) research center in London. The American drugmaker cited Britain's sluggish progress on life sciences investment and what it called the chronic undervaluation of innovative medicines by successive governments.
That's the kind of blow the UK government is trying to prevent with this initiative. By bringing industry leaders into the room early, officials are hoping to design a system that keeps the NHS affordable while making the UK attractive enough for pharmaceutical companies to keep investing, researching, and manufacturing there. It's a delicate balance, and they've got three years to figure it out.
